HIV news from aidsmap.com

Broadly neutralising antibody plus cabotegravir maintains viral suppression for at least a year
A broadly neutralising antibody from ViiV Healthcare, now named lotivibart, could potentially be paired with cabotegravir injections for long-acting HIV treatment, according to the latest results from the EMBRACE study presented last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2026) in Denver.
>> Read more

Half the participants from placebo arm of HIV cure trial have prolonged viral load remission when given broadly neutralising antibodies
In the second phase of the RIO HIV cure trial, participants originally given a placebo were offered the experimental therapy, the Conference on Retroviruses and Opportunistic Infections (CROI 2026) heard last week. More than half of them responded with a prolonged period of low or undetectable viral load and were able to put off resuming their HIV therapy for more than 20 weeks. Two are still off antiretroviral therapy (ART) after more than a year. [GLOSSARY]
>> Read more

Major US cohort reveals sharp racial disparities in HIV acquisition among trans women
At the Conference on Retroviruses and Opportunistic Infections (CROI 2026) held in Denver last week, Dr Sari Reisner from the University of Michigan presented data on how many transgender women in a national US cohort acquired HIV over a two-year period, and the factors associated with getting HIV. “Our study found that HIV incidence remains high among trans women in the US and that disparities persist across race and ethnicity, with highest HIV incidence for Black, Latina and Asian trans women,” Reisner stated.
>> Read more